HIV in Pregnancy

Aka: HIV in Pregnancy, Perinatal HIV Transmission, Pregnancy Related HIV Concerns, Maternal HIV

advertisement

II. Epidemiology

  1. Women with AIDS are young: >80% are between ages 18-44 years
  2. HIV Prevalence in U.S. obstetrics patients: 1-5%
  3. Risks of vertical transmission
    1. HIV Viral Load <1000 copies per ml: 2% transmission
    2. HIV Viral Load >1000 copies/ml
      1. Untreated woman with HIV: 25% transmission
      2. AZT used intrapartum: 5-8% transmission
      3. AZT and Ceserean delivery: 2% transmission
  4. Perinatal HIV Infection
    1. Neonatal HIV has been reduced 95% since the 1990s in the U.S.
    2. Of the 5000 infants born to HIV mothers in U.S. per year, 73 infants acquired HIV Infection (2017)
    3. Taylor (2017) JAMA Pediatr 171(5): 435-42 [PubMed]
  5. Racial discrepancy in Perinatally acquired HIV in United States (2009, CDC)
    1. Black patients: 9.9 in 100,000 live births
    2. Hispanic patients: 1.7 in 100,000 live births
    3. White patients: 0.1 in 100,000 live births
    4. http://www.cdc.gov/hiv/risk/gender/pregnantwomen/index.html

III. Risk Factors: Perinatal HIV Transmission Factors

  1. Risks of transmissions (13-39% with Zidovudine)
    1. Higher levels of maternal viremia (>1000 copies/ml)
    2. HIV core Antigenemia
    3. Lower maternal CD4 Count
    4. Advanced clinical HIV disease
    5. Maternal immune factors and Viral factors
    6. Primary HIV Infection during pregnancy
    7. Chorioamnionitis
    8. Other Sexually Transmitted Disease
    9. Unprotected intercourse during pregnancy
    10. "Hard drug" use during pregnancy
    11. Invasive monitoring (e.g. fetal scalp electrodes)
    12. Premature birth or low birthweight infant
    13. Rupture of Membranes
      1. Artificial Rupture of Membranes
      2. Delivery more than 4 hours after ruptured membranes
    14. Instrumental deliveries (i.e. forceps or vacuum)
    15. DeLee Suction
    16. Vaginal Delivery
    17. Advanced maternal age
    18. First born of twins born to an HIV infected mother
  2. Factors that decrease risk of transmission
    1. Higher levels of neutralizing HIV Antibody titers
      1. Antibodies to certain Epitopes of GP 120
    2. Elective Cesarean Section
    3. Zidovudine (AZT)
    4. Less invasive monitoring and intrapartum procedures

IV. Mechanisms: Vertical Transmission (Maternal to Child)

  1. Responsible for 90% of Pediatric HIV cases
  2. In Utero transmission (30%)
    1. Detected by PCR or Blood Culture
      1. Cord blood can not be used
      2. Results obtained in <48 hours
    2. Intrauterine HIV Transmission occurs early pregnancy
      1. Study of 124 HIV+ obstetric patients over 4 years
      2. Spontaneous Abortions 14 (11%) between 8-32 weeks
        1. HIV Positive on autopsy: 7 of 14 fetuses (50%)
      3. Reference
        1. Langston (1995) J Infect Dis 172:1451-60 [PubMed]
    3. Worse outcome then intrapartum transmission
      1. Associated with rapid HIV progression
      2. Newborn predictors of rapid course
        1. Hepatosplenomegaly
        2. Lymphadenopathy
        3. CD4+ Lymphocytes <30%
        4. HIV PCR positive within first week of life
        5. Mayaux (1996) JAMA 275:606-10 [PubMed]
  3. Intrapartum Transmission (70%)
    1. Mechanism
      1. Direct contact with maternal genital secretions
      2. Maternal-fetal micro transfusions
        1. Occur during labor as in Hepatitis B
      3. Possible ascending infections
        1. Similar mechanism as Group B Streptococcus
        2. Increased transmission if Membranes Ruptured > 4h
    2. Infants subsequent Cultures
      1. Negative Culture or PCR within first 48 hours
      2. Positive Culture within 7-90 days after birth
    3. Increased intrapartum transmission risk factors
      1. Women not on HIV Antiretroviral therapy (or <4 weeks of treatment before delivery)
      2. Advanced Maternal HIV disease
      3. HIV RNA load >50 copies/ml (insufficient HIV suppression, indicating Cesarean Section)
        1. HIV Viral Load >1000 copies/ml is associated with highest risk of vertical transmission
      4. First twin delivered
  4. Postpartum transmission
    1. Breast Feeding is contraindicated in Maternal HIV

V. Labs

  1. Prenatal HIV Testing should be encouraged for all women
    1. Universal HIV Screening for all women as part of Prenatal Labs
      1. If HIV positive, start Antiretroviral therapy at time of diagnosis
    2. Re-test HIV Negative women in third trimester if high risk (e.g. IVDA, STD risk, sex work)
    3. Expedited HIV Test for HIV status unknown in active labor presentation
      1. If HIV positive, start intrapartum Zidovudine for mother and Antiretrovirals for infant on delivery
  2. See Pediatric HIV (for testing in the infant)
  3. Viral load and CD4 Count baseline and in each trimester
  4. PPD in second trimester

VI. Management: General Measures

  1. Treat all Sexually Transmitted Diseases
  2. Prevent opportunistic infections
  3. Diagnose Maternal HIV early
  4. Delivery within 4 hours of Rupture of Membranes
  5. Delivery by elective, scheduled Cesarean Section at 38 weeks
    1. NSVD may be considered if viral load <1000 copies/ml
    2. Cesarean Section does not reduce transmission if
      1. Labor starts prior to ceserean
      2. Spontaneous Rupture of Membranes
    3. Use best clinical evidence to estimate gestation
      1. Avoid Amniocentesis
    4. Use prophylactic Antibiotics during Ceserean Section
      1. Most indicated in lower CD4 Counts
  6. Lactation is contraindicated (risk of HIV Transmission)
  7. Update Vaccinations as needed
    1. Influenza Vaccine
    2. Pneumococcal Vaccine

VII. Management: Anti-Retroviral Therapy

  1. Treat HIV-infected pregnant women and infants!
    1. Mother on Antiretroviral drugs after 14 weeks
      1. NIH recommends same treatment as non-pregnant
      2. Consider multiple Retroviral drugs
      3. Includes the use of Protease Inhibitors
      4. (1999) MMWR Morb Mortal Wkly Rep 47(RR-5):1-41 [PubMed]
    2. Intravenous Zidovudine (ZDV) during labor
    3. Infants treated in first 6 weeks of life
  2. Decreases likelihood of maternal-infant transmission
    1. Zidovudine (ZDV) reduces overall transmission 25% to 8%
    2. Peripartum ZDV reduces transmission by 30%
  3. Zidovudine (ZDV) Protocol for HIV positive Mothers
    1. Antepartum (start at 14 weeks gestation)
      1. Consider multi-Antiretroviral drug therapy
      2. Zidovudine (AZT) 100 mg PO 5 times per day
    2. Intrapartum
      1. Indicated for HIV RNA Load >1000 copies/ml at delivery (or unknown viral load)
      2. Load: AZT 2 mg/kg over 1 hour
      3. Maintenance: AZT 1 mg/kg/hour until delivery
    3. Newborn
      1. See Pediatric HIV for Newborn HIV Prophylaxis protocol
      2. HIV Prophylaxis started within 6 hours of delivery
    4. Other protocols
      1. Nevirapine appears more effective than AZT
        1. Nevirapine protocols were being developed as of 20 years ago, but ZDV continues to be mainstay
        2. Guay (1999) Lancet 354:795-802 [PubMed]

VIII. Resources

  1. See HIV Resources
  2. Antiretroviral Pregnancy Registry
    1. Phone: 800-258-4263

IX. References

  1. (1997) Int J Gynaecol Obstet 57:73-80 [PubMed]
  2. Krist (2001) Am Fam Physician 63(1):107-122 [PubMed]
  3. Krist (2002) Am Fam Physician 65(10):2049-56 [PubMed]
  4. Lindegren (1999) JAMA 282:531-8 [PubMed]
  5. Landesman (1996) N Engl J Med 334:1617-23 [PubMed]
  6. Vijayan (2021) Am Fam Physician 104(1): 58-62 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "HIV in Pregnancy." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Related Topics in Obstetrics

advertisement